The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.
Alice Dewdney
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Merck (U); Roche (U)
Honoraria - Roche
Research Funding - Merck Serono; Roche; Sanofi
Jaume Capdevila
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono; Roche
Diana M. Tait
No relevant relationships to disclose
Gina Brown
No relevant relationships to disclose
Andrew Wotherspoon
No relevant relationships to disclose
David Gonzalez de Castro
No relevant relationships to disclose
Sanna Hulkki Wilson
No relevant relationships to disclose
Yu Jo Chua
Honoraria - Roche
Rachel Wong
Consultant or Advisory Role - Roche
Honoraria - Roche
Yolanda Barbachano
No relevant relationships to disclose
Jacqueline Rose Oates
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Merck; Roche (U); Sanofi
Honoraria - Merck; Roche; Sanofi
Research Funding - Amgen; Merck
Expert Testimony - Amgen (U)